CN107260711A - A kind of pharmaceutical composition for treating breast cancer and its application - Google Patents
A kind of pharmaceutical composition for treating breast cancer and its application Download PDFInfo
- Publication number
- CN107260711A CN107260711A CN201710372408.5A CN201710372408A CN107260711A CN 107260711 A CN107260711 A CN 107260711A CN 201710372408 A CN201710372408 A CN 201710372408A CN 107260711 A CN107260711 A CN 107260711A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- breast cancer
- pentenols
- trans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention belongs to a kind of pharmaceutical composition for treating breast cancer and its application；The pharmaceutical composition is formulated comprising following raw materials according：The trans alcohol of 2 hexene 1, suitable 2 pentenols, the alcohol of 1 octene 3；With can effectively treat breast cancer and effect substantially, Quality Control stabilization is suitable to the advantage of patient's long-term taking.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to a kind of pharmaceutical composition for treating breast cancer and its application.
Background technology
Breast cancer is that occur the malignant tumour in mammary gland galandular epithelium tissue.Female mammary gland is by skin, fibr tissue, mammary gland
What body of gland and fat were constituted, 99% occurs in women in breast cancer, and male only accounts for 1%.According to National Cancer Center and Ministry of Public Health's disease
The pathogenesis of breast carcinoma data in 2009 that sick prevention and control office announces for 2012 are shown：National tumour registration area breast cancer incidence
The 1st of female malignant is occupied, the female mammary gland cancer morbidity whole nation adds up to 42.55/10 ten thousand, and city is 51.91/10
Ten thousand, rural area is 23.12/10 ten thousand.
At present, not yet there are preferably treatment mammary gland carcinogenesis and the medicine of development.Doctor can according to tumour by stages and
The health of patient, as one sees fit using operation, radiotherapy, chemotherapy, endocrine therapy, Biological target therapy and traditional Chinese medicine auxiliary treatment
Etc. multiple means.
The content of the invention
It is an object of the invention to overcome defect of the prior art stable there is provided a special quality control, safely and effectively, natural nothing
Poison and a kind of pharmaceutical composition for treating breast cancer suitable for long-term taking and its application.
The object of the present invention is achieved like this：The pharmaceutical composition is formulated comprising following raw materials according：Trans -2- oneself
Alkene -1- alcohol, cis- 2- pentenols, 1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1~100 part of -2- hexen-1-ols, 8~100 parts of cis- 2- pentenols, 10~100 parts of 1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1~80 part of -2- hexen-1-ols, 8~80 parts of cis- 2- pentenols, 10~80 parts of 1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1~50 part of -2- hexen-1-ols, 8~50 parts of cis- 2- pentenols, 10~50 parts of 1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1 part of -2- hexen-1-ols, 8 parts of cis- 2- pentenols, 15 parts of 1-OCOL.
The invention provides application of the aforementioned pharmaceutical compositions in the pharmaceutical composition for preparing treatment breast cancer.
Trans -2- hexen-1-ols of the present invention, cis- 2- pentenols, 1-OCOL can be directly by commercially available
Obtain, can also be obtained by plant extract.The present invention pulverizes and sieves above-mentioned raw materials respectively by weight, mixes, and loads
Capsule is compressed to tablet；Or mixed with pharmaceutically acceptable carrier or diluent, it is reloaded into capsule or is compressed to tablet.
Present invention also offers the instructions of taking of described pharmaceutical composition, its dose is in terms of said composition：Adult, 50~
100mg/ times, 3 times/day, you can reach the effect for the treatment of breast cancer clinical symptoms, particularly point out, the special population such as pregnant woman is taken
When need to follow the doctor's advice, its special adverse reaction is not yet found at present.Treatment of the present invention means the treatment after morbidity, does not represent
The intervention of premorbid.
Heretofore described trans -2- hexen-1-ols, molecular formula is C6H120, and molecular weight is 100.16, molecular structure
Formula is：
Cis- 2- pentenols, molecular formula is C5H100, and molecular weight is 86.13, and molecular structural formula is：
1-OCOL, molecular formula is C8H160, and molecular weight is 128.21, and molecular structural formula is：
Find according to the study, trans -2- hexen-1-ols, cis- 2- pentenols, the composition of 1-OCOL composition are in mouse
Breast cancer tumor growth can be suppressed in vivo.The specific present invention is by breast cancer cell tumor-bearing mice tumour growth volume
Observation, it is found that trans -2- hexen-1-ols, cis- 2- pentenols, the composition of 1-OCOL composition can press down in Mice Body
Breast cancer tumor growth processed, reduces tumor weight, increases tumor control rate, body weight is had no significant effect.
The present invention, which has, can effectively treat breast cancer and effect is obvious, the stable advantage suitable for patient's long-term taking of Quality Control.
Brief description of the drawings
Fig. 1 is pharmaceutical composition of the present invention on the influence of tumor-bearing mice shape of tumor (naked eyes are seen).
Embodiment
The present invention is a kind of pharmaceutical composition for treating breast cancer and its application, and the pharmaceutical composition is matched somebody with somebody comprising following raw materials according
System is formed：Trans -2- hexen-1-ols, cis- 2- pentenols, 1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1~100 part of -2- hexen-1-ols, 8~100 parts of cis- 2- pentenols, 10~100 parts of -1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1~80 part of -2- hexen-1-ols, 8~80 parts of cis- 2- pentenols, 10~80 parts of 1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1~50 part of -2- hexen-1-ols, 8~50 parts of cis- 2- pentenols, 10~50 parts of 1-OCOL.
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1 part of -2- hexen-1-ols, 8 parts of cis- 2- pentenols, 15 parts of 1-OCOL.
The invention provides application of the aforementioned pharmaceutical compositions in the pharmaceutical composition for preparing treatment breast cancer.
In order to more clearly explain the present invention, it is further described in conjunction with specific embodiment.It is specific real
Under applying for example：
Embodiment one
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 0.9 part of -2- hexen-1-ols, 101 parts of cis- 2- pentenols, 103 parts of 1-OCOL.
Embodiment two
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 102 parts of -2- hexen-1-ols, 7 parts of cis- 2- pentenols, 102 parts of 1-OCOL.
Embodiment three
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 101 parts of -2- hexen-1-ols, 103 parts of cis- 2- pentenols, 8.7 parts of 1-OCOL.
Example IV
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1 part of -2- hexen-1-ols, 8 parts of cis- 2- pentenols, 10 parts of 1-OCOL.
Embodiment five
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 100 parts of -2- hexen-1-ols, 100 parts of cis- 2- pentenols, 100 parts of 1-OCOL.
Embodiment six
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 50.5 parts of -2- hexen-1-ols, 54 parts of cis- 2- pentenols, 55 parts of 1-OCOL.
Embodiment seven
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 80 parts of -2- hexen-1-ols, 80 parts of cis- 2- pentenols, 80 parts of 1-OCOL.
Embodiment eight
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 40.5 parts of -2- hexen-1-ols, 44 parts of cis- 2- pentenols, 45 parts of 1-OCOL.
Embodiment nine
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 50 parts of -2- hexen-1-ols, 50 parts of cis- 2- pentenols, 50 parts of 1-OCOL.
Embodiment ten
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 25.5 parts of -2- hexen-1-ols, 29 parts of cis- 2- pentenols, 30 parts of 1-OCOL.
Embodiment 11
A kind of pharmaceutical composition for treating breast cancer, the pharmaceutical composition is comprising following raw materials according according to parts by weight preparation
Into：Trans 1 part of -2- hexen-1-ols, 8 parts of cis- 2- pentenols, 15 parts of 1-OCOL.
Above-described embodiment is only intended to clearly illustrate example of the present invention, and the not restriction to embodiment.
For the general technical staff of art, other various forms of changes can also be made on the basis of the above description
Or change.There is no necessity and possibility to exhaust all the enbodiments, and the obvious change thus amplified out
Or among changing still in the invention scope of the claims.
The present invention can be by being prepared into various differences to trans -2- hexen-1-ols, cis- 2- pentenols, 1-OCOL
The medicament of form, such as：The forms such as aqueous solvent, powder and mixture；Medicine is weighed according to following weight when needing to prepare aqueous solvent,
Trans -2- hexen-1-ols 8mg, cis- 2- pentenols 9mg, 1-OCOL 15mg, mix, are dissolved in tri-distilled water, packing.
When needing to prepare powder medicine, trans -2- hexen-1-ols 0.8g, cis- 2- pentenols 0.9g, 1- are weighed according to following weight
Octene -3- alcohol 1.5g, mixing, packing.When needing to prepare mixture medicine is weighed according to following deal, trans -2- hexenes -
1- alcohol 0.8g, cis- 2- pentenols 0.9g, 1-OCOL 1.5g, mixing, packing, filling capsule.
Test example：The detection present invention is to tumor-bearing mice body weight, shape of tumor, tumor weight, gross tumor volume, tumor control rate
Influence.
1st, medicine：Trans -2- hexen-1-ols, cis- 2- pentenols, 1-OCOL are from the huge scientific and technological limited public affairs of victory in Hubei
Department purchases.
2nd, animal and cell：4T1 mouse mastopathy cells are purchased from Chinese Academy of Sciences's Shanghai cell bank, and BALB/c mouse is purchased from Beijing
Tie up the magnificent experimental animal Technology Co., Ltd. of tonneau.
3rd, experiment packet：Cellar culture cell, 1 × 10 is adjusted to by cell concentration7/ml.Take 30 BALB/c mouses, every
Flank wall injects 0.1ml cells.Mouse is divided into 6 groups, every group 6 at random.(1) model group：Tumour cell is planted, is not administered；(2)
CTX groups：Inoculated tumour cell, intraperitoneal injection of cyclophosphamide 25mg/kg；(3) present composition 100mg/kg groups：Inoculated tumour
Cell, intraperitoneal injection present composition 100mg/kg；(4) present composition 200mg/kg groups：Inoculated tumour cell, abdominal cavity
Inject present composition 200mg/kg；(5) present composition 400mg/kg groups：Inoculated tumour cell, is injected intraperitoneally this hair
Bright composition 400mg/kg (6) present composition 800mg/kg groups：Inoculated tumour cell, is injected intraperitoneally the present composition
800mg/kg；
4th, experiment content：Body weight, shape of tumor, tumor weight, gross tumor volume, tumor control rate.
5th, statistical method：All data are with mean ± standard deviationRepresent.Group difference compare with ANOVA and
Newman-Student Multiple range tests；T check analyses, are completed by the statistical softwares of SPSS 13.0, and bilateral P ＜ 0.05 think difference
There is conspicuousness.
6th, result
After 6.1 mouse inoculation 4T1, each group can touch hypodermic tumour at the 6th day.Present composition 100mg/kg,
Tetra- dosage groups of 200mg/kg, 400mg/kg, 800mg/kg have inhibitory action to breeding in 4T1 tumour cell bodies, wherein originally
Inventive composition 400mg/kg groups and CTX group gross tumor volumes are significantly less than negative control group (P ＜ 0.05), above-mentioned two groups of tumour inhibiting rates
Respectively 50.52% and 27.86%.(being shown in Table 1)
Influence of the present invention of table 1 to 4T1 tumor-bearing mice tumour growths
The results are expressed as* P ＜ 0.05as compared with group 1.
After 6.2 mouse inoculation 4T1, each group can touch hypodermic tumour at the 6th day.As shown in figure 1, the present composition
Tetra- dosage groups of 100mg/kg, 200mg/kg, 400mg/kg, 800mg/kg have suppression to make to breeding in 4T1 tumour cell bodies
With gross tumor volume is obviously reduced, and wherein composition 400mg/kg groups and CTX groups gross tumor volume reduce the most obvious；Shown in Fig. 1
Model group be (1), CTX groups are (2), and present composition 100mg/kg groups are (3), and present composition 200mg/kg groups are
(4), present composition 400mg/kg groups are (5), and present composition 800mg/kg groups are (6).
Pharmaceutically acceptable carrier of the present invention or the form and feature of diluent are by by mixed activity
Amount, method of administration, physiological disposition (including absorb, be distributed, be metabolized, drain) and the other known variable of composition are determined.
Necessarily " acceptable ", i.e., they should can be adapted to these carriers with other compositions of preparation, not interfere with the effect of said preparation
And it is not detrimental to the recipient of said preparation.For example, used pharmaceutical carriers can be solid or liquid.Solid carrier
Example be lactose, carclazyte, sucrose, talcum powder, gelatin, agar, pectin, gum arabic, magnesium stearate, stearic acid, poly- second
Glycol, polyvinylpyrrolidone, collagen hydrolysate etc..The example of liquid-carrier is phosphate buffered saline solution, syrup, breast
Liquid, wetting agent, sterile solution etc..Similarly, carrier or diluent may include time delay material well known in the art, such as individually
Glycerin monostearate or distearin or the mixture with wax.Large-scale medicament forms can be used.Therefore, such as
Fruit uses solid carrier, and said preparation can be placed on hard gelatine capsule, into lozenge or lozenge with piece agent, with powder or particle form
Form.The change of the amount of solid carrier will be very big, but preferably about 50mg to about 1g.When using liquid-carrier, preparation can
With into the form of syrup, emulsion, soft gelatine capsule.
Claims (6)
1. a kind of pharmaceutical composition for treating breast cancer, it is characterised in that：The pharmaceutical composition is formulated comprising following raw materials according：
Trans -2- hexen-1-ols, cis- 2- pentenols, 1-OCOL.
2. a kind of pharmaceutical composition for treating breast cancer according to claim 1, it is characterised in that：The pharmaceutical composition bag
It is formulated containing following raw materials according according to parts by weight：Trans 1~100 part of -2- hexen-1-ols, 8~100 parts of cis- 2- pentenols,
10~100 parts of 1-OCOL.
3. a kind of pharmaceutical composition for treating breast cancer according to claim 1, it is characterised in that：The pharmaceutical composition bag
It is formulated containing following raw materials according according to parts by weight：Trans 1~80 part of -2- hexen-1-ols, 8~80 parts of cis- 2- pentenols, 1-
10~80 parts of octene -3- alcohol.
4. a kind of pharmaceutical composition for treating breast cancer according to claim 1, it is characterised in that：The pharmaceutical composition bag
It is formulated containing following raw materials according according to parts by weight：Trans 1~50 part of -2- hexen-1-ols, 8~50 parts of cis- 2- pentenols, 1-
10~50 parts of octene -3- alcohol.
5. a kind of pharmaceutical composition for treating breast cancer according to claim 1, it is characterised in that：The pharmaceutical composition bag
It is formulated containing following raw materials according according to parts by weight：Trans 1 part of -2- hexen-1-ols, 8 parts of cis- 2- pentenols, 1-OCOL
15 parts.
6. a kind of application of pharmaceutical composition as described in claim 1-5 in the pharmaceutical composition for preparing treatment breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710372408.5A CN107260711A (en) | 2017-05-15 | 2017-05-15 | A kind of pharmaceutical composition for treating breast cancer and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710372408.5A CN107260711A (en) | 2017-05-15 | 2017-05-15 | A kind of pharmaceutical composition for treating breast cancer and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107260711A true CN107260711A (en) | 2017-10-20 |
Family
ID=60064157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710372408.5A Pending CN107260711A (en) | 2017-05-15 | 2017-05-15 | A kind of pharmaceutical composition for treating breast cancer and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107260711A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104560402A (en) * | 2014-12-31 | 2015-04-29 | 广东东阳光药业有限公司 | Tricholoma matsutake extract oil and preparation method thereof |
-
2017
- 2017-05-15 CN CN201710372408.5A patent/CN107260711A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104560402A (en) * | 2014-12-31 | 2015-04-29 | 广东东阳光药业有限公司 | Tricholoma matsutake extract oil and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| ANITA BANSAL,ETAL: "Chemical Composition and Bioactivity of the Leaf Oil of Calyptranthes pallens (Poir.) Griseb. from Abaco Island,Bahamas", 《NATURAL PRODUCT COMMUNICATIONS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103861079B (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| TWI598104B (en) | Use of Antrodia cinnamomea extract to improve side effects of chemotherapy | |
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN102475698B (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
| CN106389477B (en) | A kind of preparation method and application of the full cellular plant oil extract of Gordonia terrae | |
| CN108186794A (en) | A kind of Chinese medicine composition for treating malignant tumour and its preparation method and application | |
| CN107260711A (en) | A kind of pharmaceutical composition for treating breast cancer and its application | |
| CN104688722B (en) | Purposes of the epimedium aglucone in preparation prevention or treatment bone marrow suppression drug | |
| CN109731019B (en) | A composition with chemotherapy synergistic effect comprises components, preparation and application | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| TW201808316A (en) | Use of compositions of water/alcohol extracts of Antrodia cinnamomea cut-log cultivated fruiting body and solid-state cultivated mycelium as auxiliaries for anti-cancer agents | |
| CN104001117A (en) | Cervical-cancer-resistant composition and application thereof | |
| CN109010495A (en) | A kind of Chinese medicine composition and its preparation method and application | |
| CN103191267A (en) | Traditional Chinese medicine composition for treating liver cancers | |
| CN104523698B (en) | Application of the hederagenin in preparation anti-endometrial cancer cell HEC-1 tumour medicine | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN103830262A (en) | Auxiliary drug used for treating cancer, and applications thereof | |
| CN107019771A (en) | A kind of antineoplastic Chinese medicine composition | |
| CN107927745B (en) | A Chinese medicinal health food composition, and its preparation method and preparation | |
| CN107233334A (en) | A kind of pharmaceutical composition for adjusting immunity and its application | |
| CN104000965A (en) | Lung-cancer-resistant composition and application thereof | |
| CN104000880A (en) | Colon-cancer-resistant composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171020 |
|
| RJ01 | Rejection of invention patent application after publication |